Jean Coutu Group (PJC) (A)

PJC.A-T

Analysis and Opinions about PJC.A-T

Signal
Opinion
Expert
SELL STRENGTH
SELL STRENGTH
April 27, 2017

He does not hold because of valuation and that the sector is one that he does not need to be in. If you are sitting on gains, there is nothing wrong with taking them. It may go up because of share buybacks, however.

He does not hold because of valuation and that the sector is one that he does not need to be in. If you are sitting on gains, there is nothing wrong with taking them. It may go up because of share buybacks, however.

Mohsin Bashir
VP Investments, Stone Asset Management
Price
$23.320
Owned
No
BUY
BUY
August 19, 2016

Operates pharmacies primarily in Québec. He likes the space and it does meet his criteria. Their cash ROE is just shy of 30%, and their cash ROE/PE metric is about 2.67. Based on those metrics, this would be a good one to own.

Operates pharmacies primarily in Québec. He likes the space and it does meet his criteria. Their cash ROE is just shy of 30%, and their cash ROE/PE metric is about 2.67. Based on those metrics, this would be a good one to own.

Jason Del Vicario
Portfolio Manager, HollisWealth
Price
$19.100
Owned
No
DON'T BUY
DON'T BUY
March 15, 2016

Because of the Québec base and lack of growth, he wouldn’t go to this.

Because of the Québec base and lack of growth, he wouldn’t go to this.

Bruce Campbell (1)
President, Campbell and Lee InvMngmnt
Price
$20.950
Owned
No
COMMENT
COMMENT
January 19, 2016

In retail, he would be looking at off-price retail or convenience. Alimentation Couch-Tard (ATD.B-T) is one. Jean Coutu is down about 10%-11% from its highs and is underperforming the group. Likes the consumer, but wants to own one that has a bit of a tailwind.

In retail, he would be looking at off-price retail or convenience. Alimentation Couch-Tard (ATD.B-T) is one. Jean Coutu is down about 10%-11% from its highs and is underperforming the group. Likes the consumer, but wants to own one that has a bit of a tailwind.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$17.810
Owned
Unknown
DON'T BUY
DON'T BUY
December 21, 2015

He does not know the seasonality on this one. The chart is not so good. The stock is in a downward trend and may be trying to find support above $18. It is underperforming the market, below the 20 day moving average, and the momentum indicators are on the downside. There is insufficient reason to buy at these levels. Watch it to see if it bottoms.

He does not know the seasonality on this one. The chart is not so good. The stock is in a downward trend and may be trying to find support above $18. It is underperforming the market, below the 20 day moving average, and the momentum indicators are on the downside. There is insufficient reason to buy at these levels. Watch it to see if it bottoms.

Don Vialoux
Research Analyst, TimingTheMarket.CA & EquityClock.COM
Price
$18.160
Owned
Unknown
COMMENT
COMMENT
December 4, 2015

Governments are getting really difficult to deal with if you are a pharmacy. This is a good space because healthcare is a growing area, but there are these little headwinds that can give you pause.

Governments are getting really difficult to deal with if you are a pharmacy. This is a good space because healthcare is a growing area, but there are these little headwinds that can give you pause.

Fabrice Taylor
Publisher, The President's Club Newsletter
Price
$18.000
Owned
Unknown
COMMENT
COMMENT
September 4, 2015

The seasonality on this tends to positive in the summer. The stock tends to peak out around the middle of September, so we are getting close to the end of a period of seasonal strength. Technically the trend is down, but seems to be trying to form a base. Trading below its 20 day moving average which is not so good. Short-term momentum indicators are slightly positive. The time to take profits is probably from the middle to the end of September.

The seasonality on this tends to positive in the summer. The stock tends to peak out around the middle of September, so we are getting close to the end of a period of seasonal strength. Technically the trend is down, but seems to be trying to form a base. Trading below its 20 day moving average which is not so good. Short-term momentum indicators are slightly positive. The time to take profits is probably from the middle to the end of September.

Don Vialoux
Research Analyst, TimingTheMarket.CA & EquityClock.COM
Price
$20.640
Owned
Unknown
WATCH
WATCH
August 24, 2015

In the downturn this stock most definitely took out its past lows. Had been making a higher lows and higher highs and the last low of around $24 definitely broke. It may be starting to put in a base, but he would like to see it bounce around a bit and find support at around $19 before buying.

In the downturn this stock most definitely took out its past lows. Had been making a higher lows and higher highs and the last low of around $24 definitely broke. It may be starting to put in a base, but he would like to see it bounce around a bit and find support at around $19 before buying.

Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$19.540
Owned
Unknown
WATCH
WATCH
August 17, 2015

There was some news recently on prescriptions in Quebec, similar to Shoppers a couple of years ago. He likes the pharmacy business, however.

There was some news recently on prescriptions in Quebec, similar to Shoppers a couple of years ago. He likes the pharmacy business, however.

Ryan Bushell
President, Newhaven Asset Management
Price
$20.670
Owned
Unknown
BUY
BUY
August 14, 2015

This has been under pressure because of declining generic drug prices. Pays a decent dividend and, on a valuation basis, this is a good entry point. Likes their franchise model, which means their CapX is much lower than if they were corporately owned. About 95% of the stores are franchised, so there is a reoccurring revenue stream with not a lot of capital tied up.

This has been under pressure because of declining generic drug prices. Pays a decent dividend and, on a valuation basis, this is a good entry point. Likes their franchise model, which means their CapX is much lower than if they were corporately owned. About 95% of the stores are franchised, so there is a reoccurring revenue stream with not a lot of capital tied up.

Kash Pashootan
CEO & Chief Investment Officer, First Avenue Investment Counsel
Price
$20.970
Owned
Yes
COMMENT
COMMENT
May 12, 2015

Kind of a Shoppers Drug Mart of Québec, and has a dominant position there. Stumbled very badly a few years ago making US acquisitions, but are now doing better. Has pretty much has recovered from its woes of the past. This is worth a look.

Kind of a Shoppers Drug Mart of Québec, and has a dominant position there. Stumbled very badly a few years ago making US acquisitions, but are now doing better. Has pretty much has recovered from its woes of the past. This is worth a look.

David Baskin
President, Baskin Wealth Management
Price
$22.700
Owned
No
COMMENT
COMMENT
May 8, 2015

This stock has done fabulously well. They made all of these acquisitions. The stock has, fairly far, outrun its FMV because of their tremendous momentum with acquisitions. He is not surprised that the stock is setting back. It is historically high and also high against all of his parameters too. It is expensive.

This stock has done fabulously well. They made all of these acquisitions. The stock has, fairly far, outrun its FMV because of their tremendous momentum with acquisitions. He is not surprised that the stock is setting back. It is historically high and also high against all of his parameters too. It is expensive.

Ross Healy
Chairman, Strategic Analysis Corp
Price
$23.240
Owned
Unknown
COMMENT
COMMENT
March 18, 2015

Alimenation Couche-Tard (ATD.B-T) or Jean Coutu (PJC.A-T)? He prefers Alimenation Couche-Tard.

Alimenation Couche-Tard (ATD.B-T) or Jean Coutu (PJC.A-T)? He prefers Alimenation Couche-Tard.

Mohsin Bashir
VP Investments, Stone Asset Management
Price
$26.450
Owned
Unknown
HOLD
HOLD
May 6, 2014

This has done quite well. Pharma business is attractive, but there is some sort of takeover element in this name. A growth story and very well managed. She would wait for a pullback.

This has done quite well. Pharma business is attractive, but there is some sort of takeover element in this name. A growth story and very well managed. She would wait for a pullback.

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$23.370
Owned
No
BUY WEAKNESS
BUY WEAKNESS
May 5, 2014

Thinks they are driven by money coming out of SC-T when it was acquired. They increased the dividend and this is driving the stock. They are now more shareholder friendly. Doesn’t think it will be sold in our lifetime.

Thinks they are driven by money coming out of SC-T when it was acquired. They increased the dividend and this is driving the stock. They are now more shareholder friendly. Doesn’t think it will be sold in our lifetime.

Stephen Takacsy, B. Eng, MBA
Chief Investment Officer & Portfolio Mgr, Lester Asset Management
Price
$23.150
Owned
Unknown
Showing 1 to 15 of 204 entries